Healthcare
How might the discovery of plasma biomarkers for Alzheimer's in middle-aged people affect health policies and community support programs?
Alzheimer's disease has a long preclinical phase in which neuropathological changes, such as amyloid β (Aβ) and tau pathology, accumulate over many years.1 This preclinical phase provides an opportunity for earlier disease detection and interventions to prevent or delay dementia. Emerging blood-based biomarkers provide a minimally invasive approach to assess Alzheimer's disease-related pathology and show promising diagnostic and prognostic value in symptomatic individuals.2 However, performance of these biomarkers in cognitively unimpaired, middle-aged populations remains unclear
Global